Finding a Potential Bruceine D Inhibitor for Apoptotic Resistance Protein Pancreatic Cancer Based on Molecular Docking

Armi Wulanawati; Harry Noviardi; Muhamad Sholehuddin Malik Ibrohim

doi:10.22146/ijc.25220

Finding a Potential Bruceine D Inhibitor for Apoptotic Resistance Protein Pancreatic Cancer Based on Molecular Docking

https://doi.org/10.22146/ijc.25220

Armi Wulanawati^(1*), Harry Noviardi⁽²⁾, Muhamad Sholehuddin Malik Ibrohim⁽³⁾

(1) Department of Chemistry, Faculty of Mathematics and Natural Sciences, Bogor Agricultural University, Tanjung Street, IPB Campus Dramaga, Bogor 16680, Indonesia
(2) Department of Pharmacy, Sekolah Tinggi Teknologi Industri dan Farmasi, Jl. Kumbang no. 23, Bogor 16151, Indonesia
(3) Department of Chemistry, Faculty of Mathematics and Natural Sciences, Bogor Agricultural University, Tanjung Street, IPB Campus Dramaga, Bogor 16680, Indonesia
(*) Corresponding Author

Abstract

Pancreatic cancer arises when cells in the pancreas begin to multiply out of control. In pancreatic cancer, over expression of heat proteins (Hsp70, Hsp 90), constitutive activation of NFĸB, and Bcl-2 family are closely linked with resistance to apoptosis. Apoptotic resistance has been attributed to defects in apoptotic signaling pathways. Bruceine D, which found in abundance Brucea javanica, possesses potent anti-pancreatic cancer activity. In vitro result, bruceine D could induce apoptosis of pancreatic cancer cell. The aim of this study was to find the potential effect of bruceine D inhibitor on apoptotic resistance proteins in pancreatic cancer based on molecular docking. Docking showed a binding affinity between bruceine D with proteins involved in apoptosis using AutoDock. The results showed that free binding energy of Hsp70 is -5.19; Hsp90 -7.26; NFĸB1 -5.49; NFĸB2 -6.14; Bcl-W -6.02; Bcl-xL -5.45 kcal/mol. Based on the result, we conclude that bruceine D with Hsp90 protein has potential the best binding affinity than other proteins.

Keywords

apoptotic resistance; bruceine D; inhibitor; pancreatic cancer; protein

Full Text:

Full Text PDF

References

[1] Al-Majed, H.T, El-Basmi, A.A., Al-Mohannadi, S.H., Govindan, R., and Rajakumari, G.B., 2013, Pancreatic cancer: Incidence, clinical profile, and frequency of associated factors in Kuwait, Alexandria J. Med., 49 (1), 75–80.

[2] Li, J., Wientjes, M.G., and Au, J.L.S., 2010, Pancreatic cancer: pathobiology, treatment options, and drug delivery, AAPS J., 12 (2), 223–232.

[3] Lin, L., and Leung, P.S., 2014, Use herbal medicines and natural product: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer, Int. J. Biochem. Cell Biol., 53, 224–236.

[4] Strimpakos, A.S., Syrigos, K.N., and Saif, M.W., 2010, The molecular targets for the diagnosis and treatment of pancreatic cancer, Gut Liver, 4 (4), 433–449.

[5] Xia, Y., Rocchi, P., Iovanna, J.L., and Peng, L., 2012, Targeting heat shock response pathways to treat pancreatic cancer, Drug Discovery Today,. 17 (1-2), 35-43.

[6] Long, J., Zhang, Y., Yu, X., Yang, J., LeBrun, D.G., Chen, C., Yao, Q., and Li, M., 2011, Overcoming drug resistance in pancreatic cancer, Expert Opin. Ther. Targets, 15 (7), 817–828.

[7] Lau, S.T., Lin, Z.X., Liao, Y., Zhao, M., Cheng, C.H., and Leung, P.S., 2009, Brucein D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase, Cancer Lett., 281 (1), 42–52.

[8] Leach, A.R., 2001, Molecular Modelling: Principles and Applications, Prentice Hall, New Jersey.

[9] Lestari, W., Dewi, R.T., Kardono, L.B.S., and Yanuar, A., 2017, Docking sulochrin and its derivative as α-glucosidase inhibitors of Saccharomyces cerevisiae, Indones. J. Chem., 17 (1), 144–150.

[10] The PyMOL Molecular Graphics System, Version 1.3.0.0, Schrödinger, LLC., and AutoDock programs.

[11] Atilgan, E., and Hu, J., 2011, Improving protein docking using sustainable genetic algorithms, IJCISIM, 3, 248–255.

[12] Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K., and Olson, A.J., 1998, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, J. Comput. Chem., 19 (14), 1639–1662.

[13] Gowthaman, U., JayaKanthan, M., and Sundar, D., 2008, Molecular docking studies of dithionitrobenzoic acid and its related compounds to protein disulfide isomerase: Computational screening of inhibitors to HIV-1 entry, BMC Bioinf., 9 (Suppl. 12), S14.

[14] Elokely, K.M, and Doerksen, R.J, 2013, Docking challenge: Protein sampling and molecular docking performance, J. Chem. Inf. Model., 53 (8), 1934–1945.

[15] Prabahar, A., Swaminathan, S., Loganathan, A., and Jegadeesan, R., 2015, Identification of novel inhibitors for tobacco Mosaic virus infection in Solanaceae plants, Adv. Bioinformatics, 2015, 198214.

[16] Vijesh, A.M., Isloor, A.M., Telkar, S., Arulmoli, T., and Fun, H.K., 2013, Molecular docking studies of some new imidazole derivatives for antimicrobial properties, Arabian J. Chem., 6 (2), 197–204.

[17] Paramita, R.I, Arsianti, A., and Radji, M., 2017, In silico docking studies of alkyl esters derivative of gallic acid on Bcl-xL anti-apoptotic protein of breast cancer, Int. J. ChemTech Res., 10 (1), 348–355.

[18] Tambunan, U.S.F., and Alamudi, S., 2010, Designing cyclic peptide inhibitor of dengue virus NS3-NSNS2B protease by using molecular docking approach, Bioinformation, 5(6), 250–254.

[19] Tambunan, U.S.F., Nasution, M.A.F., Parikesit, A.A., Noviardi, H., and Kerami, D., 2016, Designing of disulfide cyclic peptide for inhibiting polymerase A and B1 (PA C-PB1 N) in H1N1 virus using molecular simulation approach, OJBS, 16 (3), 122–129.

[20] Du, X., Li, Y, Xia, Y.L., Ai, S.M., Liang, J., Sang, P., Ji, X.A, and Liu S.Q, 2016, Insights into protein–ligand interactions: mechanisms, models, and methods, Int. J. Mol. Sci., 17 (2), 144.

DOI: https://doi.org/10.22146/ijc.25220